文献速递乳腺MR

乳腺癌新辅助化疗患者乳腺MRI背景实质强化与病理肿瘤反应的关系

Relationship between background parenchymal enhancement on breast MRI and pathological tumor response in breast cancer patients receiving neoadjuvant chemotherapy.
PubMed 文献 · Br J Radiol · 2018-06-05

该研究纳入186例病理确诊乳腺癌患者的372次乳腺MRI,分析新辅助化疗前后背景实质强化(BPE)与病理肿瘤反应、无复发生存及分子亚型的关系。基线BPE与病理肿瘤反应无关(p=0.2019),但化疗后BPE变化在病理完全缓解组显著大于非病理完全缓解组(p=0.0008)。BPE与无复发生存或分子亚型无显著关联,绝经前女性基线BPE高于绝经后女性(p<0.0001)。

要点

  • 化疗后BPE变化在病理完全缓解组显著大于非病理完全缓解组(p=0.0008)。
  • 基线BPE与病理肿瘤反应无显著差异(p=0.2019)。
  • 绝经前女性基线BPE高于绝经后女性(p<0.0001)。

核心结论

  • 乳腺MRI中BPE降低程度与新辅助化疗的病理肿瘤反应相关,BPE与无复发生存或分子亚型无显著差异,BPE变化可能作为肿瘤反应的生物标志物。

研究设计与样本

  • 研究纳入186例病理确诊乳腺癌患者的372次乳腺MRI,均为新辅助化疗前后行乳腺MRI检查;BPE在新辅助化疗前后各分为四类,分析其与病理肿瘤反应、无复发生存及分子亚型的关联。

关键影像表现/征象

  • 基线BPE按病理肿瘤反应分组无显著差异(p=0.2019)。
  • 新辅助化疗后BPE变化在病理完全缓解组显著大于非病理完全缓解组(p=0.0008)。
  • BPE与无复发生存或分子亚型无统计学显著关联。
  • 绝经前女性基线BPE(2.77 ± 0.86)高于绝经后女性(2.05 ± 0.69),差异有统计学意义(p < 0.0001)。
  • 基线BPE按乳腺X线实质密度分组无显著差异。

诊断标准与关键数值

  • BPE在新辅助化疗前后均分为四类。
  • 基线BPE与病理肿瘤反应比较p=0.2019,无显著差异。
  • 新辅助化疗后BPE变化在病理完全缓解组与非病理完全缓解组比较p=0.0008,差异显著。
  • 绝经前女性基线BPE 2.77 ± 0.86 vs 绝经后女性2.05 ± 0.69(p < 0.0001)。

临床应用与阅片要点

  • 作者认为BPE变化可能有潜力作为接受新辅助化疗的乳腺癌患者肿瘤反应的生物标志物。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: To evaluate the impact of background parenchymal enhancement (BPE) on breast MRI and pathological tumor responses to neoadjuvant chemotherapy (NAC) in breast cancer patients.

METHODS: A panel of 372 MRI from 186 pathologically confirmed breast cancer patients who underwent breast MRI before and after NAC were selected. BPE was classified into four categories before and after NAC. The association between BPE and the pathological tumor response to NAC, recurrence-free survival (RFS) and molecular subtypes were analyzed. We also evaluated the associations between the baseline BPE before NAC and menopausal status or mammographic parenchymal density.

RESULTS: Baseline BPE did not differ significantly according to the pathological tumor response to NAC (p = 0.2019). However, changes in BPE after NAC were significantly greater in the pathological complete remission (pCR) group than in the non-pCR group (p = 0.0008). There was no statistically significant association between BPE and RFS or molecular subtypes. The baseline BPE of pre-menopausal females (2.77 ± 0.86) were greater than those of post-menopausal females (2.05 ± 0.69), with statistical significance (p < 0.0001). Baseline BPE showed no significant difference according to mammographic parenchymal density.

CONCLUSION: The degree of BPE reduction in breast MRI correlates with the pathological tumor response to NAC in breast cancer patients. No significant difference in BPE was observed according to RFS or molecular subtypes of tumors. Advances in knowledge: This study suggests that the change in BPE may have potential as a biomarker of tumor response in breast cancer patients receiving NAC.

来源:Br J Radiol,查看原文。版权归原作者所有。

引用

  1. Oh SJ, Chae EY, Cha JH, et al. Relationship between background parenchymal enhancement on breast MRI and pathological tumor response in breast cancer patients receiving neoadjuvant chemotherapy. Br J Radiol. 2018. PMID: 29848015. doi:10.1259/bjr.20170550

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。